Commodity Channel Index
|Bid||14.00 x 1300|
|Ask||14.34 x 1000|
|Day's Range||13.52 - 14.57|
|52 Week Range||4.27 - 25.64|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.67|
NEW YORK, July 03, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc. (“Personalis” or the “Company”) (NASDAQ: PSNL). Such investors.
Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
Allogene Therapeutics, Personalis, Cortexyme, and La Jolla Pharmaceutical have all seen large stock purchases by insiders and big investors this month.
In a release issued under the same headline earlier today by Pomerantz LLP, please note that in the first sentence of the first paragraph, the investigation is on behalf of investors of Personalis, Inc. rather than Provident Financial Services, Inc. as originally stated. Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc. (“Personalis” or the “Company”) (NASDAQ: PSNL). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Personalis, Inc. ("Personalis" or "the Company") (NASDAQ: PSNL). Investors who purchased Personalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/psnl.
Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics
NEW YORK, May 28, 2020 -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Personalis, Inc. (“Personalis” or the.
PHILADELPHIA, May 28, 2020 -- Kehoe Law Firm, P.C. is investigating Personalis, Inc. (“Personalis” or the “Company”) (NASDAQ: PSNL) for potential federal securities law.
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Personalis earnings conference call. Joining me on today's call are John West, president and chief executive officer; and Aaron Tachibana, chief financial officer.
Personalis Announces Renewed Clinical Laboratory Accreditation from College of American Pathologists
Personalis Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solns for Use in Early Drug Discovery, Preclinical Studies